Comments
UK watchdog revises Amgen bone drug guidance
12.06.2012. | LONDON (Reuters) - Britain's healthcare cost watchdog has had second thoughts about using Amgen's new bone drug Xgeva, or denosumab, and now says it does not believe it should be offered on the state health service to prostate cancer patients....
